JUL 19, 2015 5:25 PM PDT

Remote Control Drug Delivery to the Brain

WRITTEN BY: Ilene Schneider
Using light to remotely activate drugs could be the next big thing in treating pain, depression, epilepsy and other neurological disorders. Researchers at Washington University in St. Louis have demonstrated the technology in mice in research funded by the National Institute on Drug Abuse, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke and the Common Fund of the National Institutes of Health. Their work on optogenetics, a technology that makes individual brain cells sensitive to light and then activates those targeted populations of cells with flashes of light, was published in Cell and reported by Jim Dryden in Futurity (http://feedly.com/i/subscription/feed/http://www.futurity.org/feed/).
Optogenetics technology administers drugs to brain cells by using light.
According to an article in Scientific American, optogenetics combines genetics and optics to control well-defined events within specific cells of living tissue. It includes "the discovery and insertion into cells of genes that confer light responsiveness; the associated technologies for delivering light deep into organisms as complex as freely moving mammals, for targeting light-sensitivity to cells of interest, and for assessing specific readouts, or effects, of this optical control." Optogenetics has the potential for control over defined events within defined cell types at defined times, a level of precision that is most likely crucial to biological understanding even beyond neuroscience. It enables scientist to understand the significance of any event in a cell in the context of the other events occurring around it in the rest of the tissue, the whole organism or even the larger environment (http://www.scientificamerican.com/article.cfm?id=optogenetics-controlling).)

As explained by co-principal investigator Michael R. Bruchas, associate professor of anesthesiology and neurobiology at Washington University in St. Louis, "In the future, it should be possible to manufacture therapeutic drugs that could be activated with light. With one of these tiny devices implanted, we could theoretically deliver a drug to a specific brain region and activate that drug with light as needed. This approach potentially could deliver therapies that are much more targeted but have fewer side effects."

While prior attempts to deliver drugs or other substances to experimental animals have necessitated tethering the animals to pumps and tubes, the new devices have four chambers to carry drugs directly into the brain. In the process of activating brain cells with drugs and light, the scientists can see the inner workings of the brain.

John A. Rogers, the study's other co-principal investigator and professor of materials science and engineering at the University of Illinois, summarizes, "We've successfully produced and demonstrated an implantable, cellular-scale microfluidic and micro-optical interface to biology, with application opportunities not only in the brain but in other parts of the nervous system and other organs as well."
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
NOV 11, 2019
Neuroscience
NOV 11, 2019
Suicidal Mitochondria Responsible for ALS
Scientists at Northwestern University have dicovered a new mechanism in the brain that may be responsable for the early stages of neurodegeneration seen in...
DEC 22, 2019
Neuroscience
DEC 22, 2019
Midlife Obesity, not Diet, Increases Dementia Risk
A new study on over 1 milion women in the UK has found that women who are obese during their 50’s are at a higher risk than women with healthier phys...
DEC 27, 2019
Drug Discovery & Development
DEC 27, 2019
Acne Drug Linked to 10 Suicides
UK regulators claim to have found a link between at least ten suicides and a powerful acne drug, manufactured under the names Roaccutane and Accutane. Alth...
JAN 09, 2020
Neuroscience
JAN 09, 2020
Why Do you Have a Higher IQ than your Grandparents?
In the 1980’s James Flynn found that on average, human intelligence quotients (IQ) increase by 3 points every 10 years. Known as the “Flynn eff...
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
JAN 16, 2020
Neuroscience
JAN 16, 2020
Early-life Stress and Pollution Lead to Cognitive Impairment
Children exposed to high levels of stress at home from early on and high levels of air pollution while still in the womb are more likely to develop attenti...
Loading Comments...